SNSE Stock Overview
An immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Sensei Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$1.94 |
| 52 Week Low | US$0.38 |
| Beta | 0.15 |
| 1 Month Change | -12.86% |
| 3 Month Change | -10.27% |
| 1 Year Change | -32.22% |
| 3 Year Change | -91.42% |
| 5 Year Change | n/a |
| Change since IPO | -97.60% |
Recent News & Updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Shareholder Returns
| SNSE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | -3.3% | -0.4% |
| 1Y | -32.2% | -2.7% | 24.8% |
Return vs Industry: SNSE underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: SNSE underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| SNSE volatility | |
|---|---|
| SNSE Average Weekly Movement | 29.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNSE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SNSE's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 28 | John Celebi | www.senseibio.com |
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
Sensei Biotherapeutics, Inc. Fundamentals Summary
| SNSE fundamental statistics | |
|---|---|
| Market cap | US$11.42m |
| Earnings (TTM) | -US$29.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs SNSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNSE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.80m |
| Earnings | -US$29.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNSE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 13:55 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sensei Biotherapeutics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Samantha Lynn Semenkow | Citigroup Inc |
| Edward White | H.C. Wainwright & Co. |